Evoque
Payments companies reported to CMS as associated with Evoque. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Evoque, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Evoque
These are the largest totals companies reported as associated with Evoque. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Brian Oneill | Detroit, MI | Cardiovascular Disease | $50,412.98 |
| Konstantinos Koulogiannis | Morristown, NJ | Cardiovascular Disease | $47,670.22 |
| Pradeep Yadav | Atlanta, GA | Interventional Cardiology | $47,367.09 |
| Jyothy Puthumana | Chicago, IL | Cardiovascular Disease | $40,881.59 |
| Santiago Garcia | Cincinnati, OH | Interventional Cardiology | $39,952.33 |
| Firas Zahr | Portland, OR | Cardiovascular Disease | $32,106.91 |
| Akhil Narang | Chicago, IL | Cardiovascular Disease | $32,047.46 |
| Thomas Waggoner | Tucson, AZ | Interventional Cardiology | $28,964.52 |
| Curtiss Stinis | La Jolla, CA | Interventional Cardiology | $25,487.64 |
| Christiane Haeffele | Stanford, CA | Cardiovascular Disease | $24,480.90 |
Prescribed Evoque?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.